Clinical trials: Schizophrenia Disorder
Schizophrenia
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
- Trial name
- NCT00088621
- Testing
- Lurasidone 80mg tablet
- Where
- 21 sites in United States
- Volunteers
- 61 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or schizoaffective disorder after 6 weeks of…
- Trial name
- NCT02901587
- Testing
- Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Hepatic Impairment
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate release (IR) paliperidone, after oral administration, in patients having moderate hepatic impairment compared to patients having normal…
- Trial name
- NCT00791284
- Testing
- Intermediate release (IR) Paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
This study is being conducted to evaluate the safety and tolerability of ascending multiple oral doses of SCA-136 adminstered to healthy Japanese and non-Japanese female subjects.
- Trial name
- NCT00458107
- Testing
- SCA-136
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) Paliperidone compared to placebo in patients with Schizophrenia.
- Trial name
- NCT00396565
- Testing
- ER OROS paliperidone, Olanzapine
- Where
- 56 sites in Japan
- Volunteers
- 394 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
7-week Study With CT-155 in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia
- Trial name
- NCT05486312
- Testing
- CT-155 smartphone app
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after repeated oral dosing to patients with schizophrenia.
- Trial name
- NCT02202226
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235559
- Testing
- bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2
- Where
- 90 sites in United States, Bulgaria and 5 more
- Volunteers
- 604 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers
GSK729327 is a selective positive allosteric modulator of AMPA-type ionotropic glutamate receptors, exhibiting equivalent potency at all AMPA receptor subtypes.
- Trial name
- NCT00448890
- Testing
- GSK729327
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Schizophrenia
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or…
- Trial name
- NCT02624167
- Testing
- NW-3509A
- Where
- 5 sites in United States, India
- Volunteers
- 90 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia.
- Trial name
- NCT00768612
- Testing
- SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)
The primary features of schizophrenia and schizoaffective disorder are positive (inability to think clearly and distinguish reality from fantasy) and negative symptoms (reduction or absence of normal behavior or emotions).
- Trial name
- ACTAMESA (NCT00212771)
- Testing
- asenapine, olanzapine
- Volunteers
- 440 people
- Sponsor
- Organon and Co
Schizophrenia, Major Depressive Disorder
"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
The objective of this post marketing surveillance is to further gather local data on the safety and efficacy of Brexpiprazole (RexultiTM) Film-coated Tablet in the treatment of schizophrenia and adjunctive therapy of Major…
- Trial name
- RAISE (NCT04641780)
- Testing
- Brexpiprazole
- Where
- Philippines
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Schizophrenia
Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
This study will investigate the safety, tolerability, PK and PD profile of AUT00206 after repeated doses in patients with stable but symptomatic schizophrenia, taking one or two established anti-psychotic drugs.
- Trial name
- NCT03164876
- Testing
- AUT00206
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Autifony Therapeutics Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.